Symbols / BBIO
BBIO Chart
About
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.09B |
| Enterprise Value | 14.39B | Income | -797.12M | Sales | 353.78M |
| Book/sh | -10.04 | Cash/sh | 3.35 | Dividend Yield | — |
| Payout | 0.00% | Employees | 725 | IPO | — |
| P/E | — | Forward P/E | 84.33 | PEG | — |
| P/S | 37.00 | P/B | -6.81 | P/C | — |
| EV/EBITDA | -25.11 | EV/Sales | 40.67 | Quick Ratio | 3.52 |
| Current Ratio | 3.88 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -4.21 | EPS next Y | 0.81 | EPS Growth | — |
| Revenue Growth | 43.18% | Earnings | 2026-04-28 | ROA | -43.48% |
| ROE | — | ROIC | — | Gross Margin | 95.78% |
| Oper. Margin | -112.97% | Profit Margin | -225.32% | Shs Outstand | 191.63M |
| Shs Float | 153.94M | Short Float | 17.47% | Short Ratio | 7.04 |
| Short Interest | — | 52W High | 84.94 | 52W Low | 28.32 |
| Beta | 1.10 | Avg Volume | 2.68M | Volume | 2.43M |
| Target Price | $98.86 | Recom | Strong_buy | Prev Close | $67.91 |
| Price | $68.31 | Change | 0.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$98.86
Mean price target
2. Current target
$68.31
Latest analyst target
3. DCF / Fair value
$-25.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$68.31
Low
$80.00
High
$157.00
Mean
$98.86
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | HC Wainwright & Co. | Buy → Buy | $100 |
| 2026-02-13 | main | Oppenheimer | Outperform → Outperform | $83 |
| 2026-02-13 | main | Wells Fargo | Overweight → Overweight | $98 |
| 2026-01-28 | init | Barclays | — → Overweight | $80 |
| 2026-01-20 | main | Wells Fargo | Overweight → Overweight | $88 |
| 2026-01-08 | main | Truist Securities | Buy → Buy | $86 |
| 2026-01-06 | init | Morgan Stanley | — → Overweight | $96 |
| 2025-12-15 | main | Leerink Partners | Outperform → Outperform | $86 |
| 2025-12-11 | init | Bernstein | — → Outperform | $94 |
| 2025-11-11 | main | Wells Fargo | Overweight → Overweight | $84 |
| 2025-11-07 | main | JP Morgan | Overweight → Overweight | $77 |
| 2025-11-03 | reit | HC Wainwright & Co. | Buy → Buy | $90 |
| 2025-10-31 | main | Goldman Sachs | Buy → Buy | $100 |
| 2025-10-30 | main | TD Cowen | Buy → Buy | $95 |
| 2025-10-30 | reit | Raymond James | Outperform → Outperform | $71 |
| 2025-10-30 | main | Cantor Fitzgerald | Overweight → Overweight | $110 |
| 2025-10-30 | main | Piper Sandler | Overweight → Overweight | $98 |
| 2025-10-30 | reit | Truist Securities | Buy → Buy | $80 |
| 2025-10-29 | main | HC Wainwright & Co. | Buy → Buy | $90 |
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $80 |
- Three late-stage drug wins move BridgeBio toward six genetic treatments - Stock Titan ue, 24 Feb 2026 21
- BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Singapore Wed, 25 Feb 2026 00
- BridgeBio Unveils Positive Results For Its Most 'Hotly Debated' Phase 3 Drug - Investor's Business Daily hu, 12 Feb 2026 08
- BBIO Stock Surges 19% With A 5-day Spree On Positive Phase 3 Trial Data - Trefis Fri, 13 Feb 2026 06
- BridgeBio Pharma director Scott sells $754k in BBIO stock - Investing.com Wed, 18 Feb 2026 23
- BridgeBio (BBIO) Q4 2025 Earnings Call Transcript - The Globe and Mail ue, 24 Feb 2026 21
- BridgeBio Pharma (BBIO) Projects Strong Cash Flow by 2028 - GuruFocus Wed, 25 Feb 2026 01
- Why BridgeBio Pharma Shares Are Sliding Despite Wins - TipRanks ue, 24 Feb 2026 22
- Biotech BridgeBio plans three March investor conference chats - Stock Titan Mon, 23 Feb 2026 12
- $BBIO stock is up 9% today. Here's what we see in our data. - Quiver Quantitative Fri, 06 Feb 2026 08
- BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? - Stocktwits hu, 12 Feb 2026 08
- Buy the Dip on This Biotech Stock After Recent Fall - Schaeffer's Investment Research Mon, 09 Feb 2026 08
- BBIO Stock In Focus As Phase 3 Results And Q3 Earnings Approach - RTTNews Mon, 27 Oct 2025 07
- Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - Yahoo Finance hu, 29 Jan 2026 08
- BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock - Investing.com hu, 19 Feb 2026 00
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 28053 | 2002717.0 | — | Sale at price 71.03 - 72.80 per share. | KUMAR NEIL | Chief Executive Officer | — | 2026-02-19 00:00:00 | D |
| 1 | 10000 | 754557.0 | — | Sale at price 74.34 - 75.93 per share. | SCOTT RANDAL W | Director | — | 2026-02-17 00:00:00 | D |
| 2 | 10000 | 167500.0 | — | Conversion of Exercise of derivative security at price 16.75 per share. | SCOTT RANDAL W | Director | — | 2026-02-17 00:00:00 | D |
| 3 | 13600 | 1016147.0 | — | Sale at price 74.71 - 75.38 per share. | TRIMARCHI THOMAS | President | — | 2026-02-17 00:00:00 | D |
| 4 | 510 | 37898.0 | — | Sale at price 74.31 per share. | APULI MARICEL | Officer | — | 2026-02-17 00:00:00 | D |
| 5 | 64698 | nan | — | — | KUMAR NEIL | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 6 | 80000 | 5748666.0 | — | Sale at price 70.69 - 73.25 per share. | KUMAR NEIL | Chief Executive Officer | — | 2026-02-11 00:00:00 | I |
| 7 | 80000 | 6043168.0 | — | Sale at price 73.64 - 78.19 per share. | KUMAR NEIL | Chief Executive Officer | — | 2026-01-09 00:00:00 | I |
| 8 | 30011 | 2239902.0 | — | Sale at price 74.60 - 75.24 per share. | KUMAR NEIL | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 9 | 60975 | nan | — | — | KUMAR NEIL | Chief Executive Officer | — | 2025-12-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 288.52K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -581.09M | -574.66M | -345.46M | -569.66M |
| TotalUnusualItems | 144.26M | 9.19M | -51.99M | 35.82M |
| TotalUnusualItemsExcludingGoodwill | 144.26M | 9.19M | -51.99M | 35.82M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -535.76M | -643.20M | -481.18M | -562.54M |
| ReconciledDepreciation | 6.08M | 6.49M | 6.77M | 5.84M |
| ReconciledCostOfRevenue | 3.88M | 2.45M | 3.43M | 3.11M |
| EBITDA | -436.83M | -565.47M | -397.44M | -533.83M |
| EBIT | -442.90M | -571.96M | -404.21M | -539.68M |
| NetInterestIncome | -82.04M | -63.25M | -72.90M | -45.65M |
| InterestExpense | 99.29M | 81.29M | 80.44M | 46.78M |
| InterestIncome | 17.25M | 18.04M | 7.54M | 1.13M |
| NormalizedIncome | -679.74M | -652.39M | -429.20M | -598.36M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -535.76M | -643.20M | -481.18M | -562.54M |
| TotalExpenses | 799.27M | 608.75M | 546.09M | 646.35M |
| TotalOperatingIncomeAsReported | -592.97M | -607.37M | -512.20M | -576.63M |
| DilutedAverageShares | 186.08M | 162.79M | 147.47M | 144.36M |
| BasicAverageShares | 186.08M | 162.79M | 147.47M | 144.36M |
| DilutedEPS | -2.88 | -3.95 | -3.26 | -3.90 |
| BasicEPS | -2.88 | -3.95 | -3.26 | -3.90 |
| DilutedNIAvailtoComStockholders | -535.76M | -643.20M | -481.18M | -562.54M |
| NetIncomeCommonStockholders | -535.76M | -643.20M | -481.18M | -562.54M |
| NetIncome | -535.76M | -643.20M | -481.18M | -562.54M |
| MinorityInterests | 7.58M | 10.05M | 3.47M | 23.91M |
| NetIncomeIncludingNoncontrollingInterests | -543.35M | -653.25M | -484.65M | -586.45M |
| NetIncomeContinuousOperations | -543.35M | -653.25M | -484.65M | -586.45M |
| TaxProvision | 1.15M | 0.00 | 0.00 | |
| PretaxIncome | -542.19M | -653.25M | -484.65M | -586.45M |
| OtherIncomeExpense | 117.22M | 9.44M | 56.68M | 35.82M |
| OtherNonOperatingIncomeExpenses | 4.14M | 256.00K | 108.67M | 35.82M |
| SpecialIncomeCharges | 136.13M | -9.13M | -43.77M | 35.82M |
| GainOnSaleOfPPE | -7.50M | 35.82M | ||
| GainOnSaleOfBusiness | 178.32M | -1.20M | 0.00 | |
| OtherSpecialCharges | 26.59M | |||
| WriteOff | 7.21M | 20.74M | ||
| ImpairmentOfCapitalAssets | 271.00K | 0.00 | 12.72M | |
| RestructuringAndMergernAcquisition | 15.33M | 7.93M | 31.05M | 0.00 |
| EarningsFromEquityInterest | -31.18M | 0.00 | 0.00 | 0.00 |
| GainOnSaleOfSecurity | 8.14M | 18.31M | -8.22M | |
| NetNonOperatingInterestIncomeExpense | -82.04M | -63.25M | -72.90M | -45.65M |
| InterestExpenseNonOperating | 99.29M | 81.29M | 80.44M | 46.78M |
| InterestIncomeNonOperating | 17.25M | 18.04M | 7.54M | 1.13M |
| OperatingIncome | -577.37M | -599.44M | -468.44M | -576.63M |
| OperatingExpense | 795.39M | 606.30M | 542.65M | 643.23M |
| ResearchAndDevelopment | 506.46M | 455.71M | 399.46M | 451.02M |
| SellingGeneralAndAdministration | 288.93M | 150.59M | 143.19M | 192.21M |
| GrossProfit | 218.02M | 6.86M | 74.21M | 66.60M |
| CostOfRevenue | 3.88M | 2.45M | 3.43M | 3.11M |
| TotalRevenue | 221.90M | 9.30M | 77.65M | 69.72M |
| OperatingRevenue | 221.90M | 9.30M | 77.65M | 69.72M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 6.19M | 6.19M | 6.19M | 6.19M |
| OrdinarySharesNumber | 190.04M | 175.08M | 150.63M | 147.34M |
| ShareIssued | 196.24M | 181.27M | 156.82M | 153.54M |
| NetDebt | 1.04B | 1.35B | 1.33B | 1.31B |
| TotalDebt | 1.73B | 1.74B | 1.72B | 1.73B |
| TangibleBookValue | -1.49B | -1.38B | -1.28B | -915.35M |
| InvestedCapital | 253.48M | 372.47M | 453.00M | 833.39M |
| WorkingCapital | 566.29M | 333.75M | 427.43M | 753.79M |
| NetTangibleAssets | -1.49B | -1.38B | -1.28B | -915.35M |
| CapitalLeaseObligations | 9.20M | 13.11M | 15.95M | 22.37M |
| CommonStockEquity | -1.47B | -1.35B | -1.25B | -870.41M |
| TotalCapitalization | 253.48M | 372.47M | 453.00M | 833.39M |
| TotalEquityGrossMinorityInterest | -1.46B | -1.34B | -1.24B | -865.58M |
| MinorityInterest | 10.29M | 11.72M | 9.69M | 4.83M |
| StockholdersEquity | -1.47B | -1.35B | -1.25B | -870.41M |
| GainsLossesNotAffectingRetainedEarnings | 8.00K | 31.00K | -328.00K | -132.00K |
| OtherEquityAdjustments | 8.00K | 31.00K | -328.00K | -132.00K |
| TreasuryStock | 275.00M | 275.00M | 275.00M | 275.00M |
| RetainedEarnings | -3.10B | -2.56B | -1.92B | -1.44B |
| AdditionalPaidInCapital | 1.90B | 1.48B | 938.70M | 841.53M |
| CapitalStock | 196.00K | 181.00K | 157.00K | 154.00K |
| CommonStock | 196.00K | 181.00K | 157.00K | 154.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.38B | 1.89B | 1.87B | 1.88B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.22B | 1.75B | 1.75B | 1.74B |
| OtherNonCurrentLiabilities | 286.00K | 5.63M | 26.64M | 22.07M |
| NonCurrentDeferredLiabilities | 496.19M | 3.73M | ||
| NonCurrentDeferredRevenue | 17.09M | 3.73M | ||
| LongTermDebtAndCapitalLeaseObligation | 1.73B | 1.74B | 1.72B | 1.72B |
| LongTermCapitalLeaseObligation | 4.70M | 8.98M | 12.27M | 17.43M |
| LongTermDebt | 1.72B | 1.73B | 1.71B | 1.70B |
| CurrentLiabilities | 154.40M | 143.84M | 121.43M | 135.07M |
| CurrentDeferredLiabilities | 14.60M | 6.10M | 8.16M | 0.00 |
| CurrentDeferredRevenue | 14.60M | 6.10M | 8.16M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 4.51M | 4.13M | 3.67M | 4.94M |
| CurrentCapitalLeaseObligation | 4.51M | 4.13M | 3.67M | 4.94M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 58.33M | 57.37M | 31.26M | 37.04M |
| PayablesAndAccruedExpenses | 76.96M | 76.25M | 78.34M | 93.09M |
| CurrentAccruedExpenses | 67.34M | 65.59M | 66.78M | 81.21M |
| InterestPayable | 11.06M | 17.76M | 17.50M | |
| Payables | 9.62M | 10.65M | 11.56M | 11.88M |
| AccountsPayable | 9.62M | 10.65M | 11.56M | 11.88M |
| TotalAssets | 919.34M | 546.38M | 623.04M | 1.01B |
| TotalNonCurrentAssets | 198.65M | 68.79M | 74.18M | 123.93M |
| OtherNonCurrentAssets | 18.20M | 22.62M | 20.22M | 33.03M |
| InvestmentsAndAdvances | 143.75M | 0.00 | ||
| LongTermEquityInvestment | 143.75M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 23.93M | 26.32M | 28.71M | 44.93M |
| OtherIntangibleAssets | 28.71M | 44.93M | ||
| NetPPE | 12.78M | 19.84M | 25.25M | 45.97M |
| GrossPPE | 12.78M | 19.84M | 25.25M | 45.97M |
| OtherProperties | 12.78M | 19.84M | 25.25M | 45.97M |
| CurrentAssets | 720.69M | 477.59M | 548.85M | 888.86M |
| OtherCurrentAssets | 34.74M | 24.30M | 21.92M | |
| RestrictedCash | 126.00K | 16.65M | 37.93M | 177.00K |
| PrepaidAssets | 21.92M | 32.27M | ||
| Receivables | 4.72M | 1.75M | 17.08M | 19.75M |
| OtherReceivables | 1.75M | 17.08M | 19.75M | |
| AccountsReceivable | 4.72M | 1.75M | ||
| CashCashEquivalentsAndShortTermInvestments | 681.10M | 434.88M | 471.92M | 836.66M |
| OtherShortTermInvestments | 0.00 | 58.95M | 95.23M | 442.89M |
| CashAndCashEquivalents | 681.10M | 375.94M | 376.69M | 393.77M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -529.63M | -529.03M | -425.81M | -546.18M |
| RepurchaseOfCapitalStock | -7.53M | -6.88M | -1.56M | -204.75M |
| RepaymentOfDebt | -473.42M | 0.00 | -20.49M | -124.12M |
| IssuanceOfDebt | 950.00M | 0.00 | 0.00 | 1.20B |
| IssuanceOfCapitalStock | 314.74M | 449.81M | 4.85M | 0.00 |
| CapitalExpenditure | -8.91M | -1.31M | -6.32M | -48.25M |
| InterestPaidSupplementalData | 91.34M | 61.11M | 54.44M | 29.77M |
| EndCashPosition | 683.24M | 394.73M | 416.88M | 396.37M |
| BeginningCashPosition | 394.73M | 416.88M | 396.37M | 358.68M |
| ChangesInCash | 288.51M | -22.15M | 20.52M | 37.69M |
| FinancingCashFlow | 748.46M | 451.54M | -13.13M | 736.45M |
| CashFlowFromContinuingFinancingActivities | 748.46M | 451.54M | -13.13M | 736.45M |
| NetOtherFinancingCharges | -43.50M | -801.00K | 837.00K | -97.65M |
| ProceedsFromStockOptionExercised | 8.16M | 9.41M | 3.22M | -40.83M |
| NetCommonStockIssuance | 307.21M | 442.93M | 3.29M | -204.75M |
| CommonStockPayments | -7.53M | -6.88M | -1.56M | -204.75M |
| CommonStockIssuance | 314.74M | 449.81M | 4.85M | 0.00 |
| NetIssuancePaymentsOfDebt | 476.58M | 0.00 | -20.49M | 1.08B |
| NetLongTermDebtIssuance | 476.58M | 0.00 | -20.49M | 1.08B |
| LongTermDebtPayments | -473.42M | 0.00 | -20.49M | -124.12M |
| LongTermDebtIssuance | 950.00M | 0.00 | 0.00 | 1.20B |
| InvestingCashFlow | 60.78M | 54.03M | 453.15M | -200.83M |
| CashFlowFromContinuingInvestingActivities | 60.78M | 54.03M | 453.15M | -200.83M |
| NetOtherInvestingChanges | -503.00K | 120.00M | 13.65M | |
| DividendsReceivedCFI | 25.68M | 0.00 | 0.00 | |
| NetInvestmentPurchaseAndSale | 44.15M | 55.84M | 339.47M | -166.23M |
| SaleOfInvestment | 158.23M | 193.11M | 532.52M | 477.04M |
| PurchaseOfInvestment | -114.08M | -137.26M | -193.06M | -643.27M |
| NetBusinessPurchaseAndSale | -140.00K | -503.00K | 0.00 | |
| PurchaseOfBusiness | -140.00K | -503.00K | 0.00 | |
| NetIntangiblesPurchaseAndSale | -7.97M | 0.00 | -1.50M | -35.00M |
| PurchaseOfIntangibles | -7.97M | 0.00 | -1.50M | -35.00M |
| NetPPEPurchaseAndSale | -933.00K | -1.31M | -4.82M | -13.25M |
| PurchaseOfPPE | -933.00K | -1.31M | -4.82M | -13.25M |
| OperatingCashFlow | -520.73M | -527.72M | -419.49M | -497.93M |
| CashFlowFromContinuingOperatingActivities | -520.73M | -527.72M | -419.49M | -497.93M |
| ChangeInWorkingCapital | 32.04M | 5.06M | 28.08M | -4.40M |
| ChangeInOtherWorkingCapital | 21.88M | -5.44M | 15.26M | 7.38M |
| ChangeInOtherCurrentLiabilities | -5.90M | -4.83M | -6.25M | -6.12M |
| ChangeInOtherCurrentAssets | 1.54M | -1.55M | 10.97M | -9.82M |
| ChangeInPayablesAndAccruedExpense | 31.42M | 4.24M | -14.75M | 35.55M |
| ChangeInAccruedExpense | 29.90M | 1.46M | -14.40M | 32.72M |
| ChangeInPayable | 1.51M | 2.78M | -349.00K | 2.83M |
| ChangeInAccountPayable | 1.51M | 2.78M | -349.00K | 2.83M |
| ChangeInPrepaidAssets | -13.92M | -2.70M | 7.67M | -4.26M |
| ChangeInReceivables | -2.97M | 15.33M | 15.17M | -19.75M |
| ChangesInAccountReceivables | -2.97M | 15.33M | 15.17M | |
| OtherNonCashItems | 17.12M | 22.34M | -88.45M | 18.50M |
| StockBasedCompensation | 95.80M | 108.71M | 91.56M | 99.50M |
| AssetImpairmentCharge | 271.00K | 0.00 | 12.72M | 0.00 |
| DepreciationAmortizationDepletion | 6.08M | 6.49M | 6.77M | 5.84M |
| DepreciationAndAmortization | 6.08M | 6.49M | 6.77M | 5.84M |
| OperatingGainsLosses | -128.68M | -17.07M | 14.48M | -30.93M |
| EarningsLossesFromEquityInvestments | 31.18M | 0.00 | 0.00 | 0.00 |
| GainLossOnInvestmentSecurities | -8.14M | -18.31M | 8.22M | -34.27M |
| GainLossOnSaleOfBusiness | -178.32M | 1.24M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -543.35M | -653.25M | -484.65M | -586.45M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BBIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|